Blockchain Registration Transaction Record

Sigyn's CardioDialysis Device Aims to Slash Heart Attack and Stroke Rates

Sigyn Therapeutics unveils CardioDialysis, a single-device technology to reduce heart attacks and strokes by clearing inflammatory molecules, deployable on existing dialysis machines for wider access.

Cardiovascular disease is the world's leading cause of death, responsible for millions of fatalities annually, with current treatments often falling short in preventing major adverse events like heart attacks and strokes. This news matters because Sigyn Therapeutics' CardioDialysis technology represents a potential breakthrough that could dramatically improve patient outcomes. By offering a more efficient, accessible, and broad-spectrum alternative to existing therapies, it addresses critical gaps in cardiovascular care. If successfully advanced, this device could reduce healthcare burdens, lower mortality rates, and provide a scalable solution for hospitals and clinics worldwide, ultimately impacting anyone at risk of or affected by heart disease.